Compare Stocks: SEM, ATAI, PACS, and CON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.39	$6.73	$3.27 ▼ $7.45	$2.74B	1.54	7.13 million shs	10.31 million shs
CON Concentra Group Holdings Parent	$34.44 -0.1%	$32.70	$18.55 ▼ $35.90	$4.39B	0.63	796,519 shs	362,551 shs
PACS PACS Group	$42.54 +0.1%	$44.66	$7.50 ▼ $49.49	$6.73B	-0.13	622,883 shs	649,460 shs
SEM Select Medical	$16.51	$16.54	$11.65 ▼ $16.99	$2.05B	1.01	3.48 million shs	N/A

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	+1.37%	+1.93%	+93.96%	+61.71%
CON Concentra Group Holdings Parent	0.00%	+0.41%	+1.42%	+35.24%	+49.07%
PACS PACS Group	0.00%	-0.79%	-12.07%	+20.97%	+280.91%
SEM Select Medical	0.00%	0.00%	0.00%	-0.45%	+26.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.39	$6.73	$3.27 ▼ $7.45	$2.74B	1.54	7.13 million shs	10.31 million shs
CON Concentra Group Holdings Parent	$34.44 -0.1%	$32.70	$18.55 ▼ $35.90	$4.39B	0.63	796,519 shs	362,551 shs
PACS PACS Group	$42.54 +0.1%	$44.66	$7.50 ▼ $49.49	$6.73B	-0.13	622,883 shs	649,460 shs
SEM Select Medical	$16.51	$16.54	$11.65 ▼ $16.99	$2.05B	1.01	3.48 million shs	N/A

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	+1.37%	+1.93%	+93.96%	+61.71%
CON Concentra Group Holdings Parent	0.00%	+0.41%	+1.42%	+35.24%	+49.07%
PACS PACS Group	0.00%	-0.79%	-12.07%	+20.97%	+280.91%
SEM Select Medical	0.00%	0.00%	0.00%	-0.45%	+26.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.06	Hold	$10.56	42.85% Upside
CON Concentra Group Holdings Parent	3.13	Buy	$37.00	7.43% Upside
PACS PACS Group	3.00	Buy	$58.80	38.22% Upside
SEM Select Medical	2.17	Hold	$16.00	-3.09% Downside

Current Analyst Ratings Breakdown

Latest SEM, ATAI, PACS, and CON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	CON Concentra Group Holdings Parent	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/4/2026	PACS PACS Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $58.00
9/2/2026	PACS PACS Group	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$62.00
8/31/2026	CON Concentra Group Holdings Parent	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/17/2026	ATAI Atai Beckley	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/13/2026	ATAI Atai Beckley	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/11/2026	CON Concentra Group Holdings Parent	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $40.00
8/10/2026	CON Concentra Group Holdings Parent	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $42.00
8/10/2026	CON Concentra Group Holdings Parent	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $42.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	670.09	N/A	N/A	$0.69 per share	10.71
CON Concentra Group Holdings Parent	$2.16B	2.03	$1.99 per share	17.27	$3.13 per share	11.00
PACS PACS Group	$5.29B	1.27	$1.60 per share	26.59	$6.08 per share	7.00
SEM Select Medical	$5.52B	0.37	$2.34 per share	7.06	$16.29 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	11/12/2026 (Estimated)
CON Concentra Group Holdings Parent	$166.41M	$1.55	22.22	19.24	1.29	8.69%	47.81%	7.04%	11/5/2026 (Estimated)
PACS PACS Group	$191.54M	$1.72	24.73	16.75	1.20	4.85%	29.55%	5.23%	11/9/2026 (Estimated)
SEM Select Medical	$146.22M	$1.06	15.58	11.55	0.95	2.42%	6.62%	2.30%	N/A

Latest SEM, ATAI, PACS, and CON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ATAI Atai Beckley	-$0.1075	-$0.09	+$0.0175	-$0.09	$0.60 million	$1.70 million
8/6/2026	Q2 2026	CON Concentra Group Holdings Parent	$0.4216	$0.52	+$0.0984	$0.51	$591.75 million	$606.03 million
8/4/2026	Q2 2026	PACS PACS Group	$0.5370	$0.63	+$0.0930	$0.47	$1.41 billion	$1.43 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
CON Concentra Group Holdings Parent	$0.25	0.73%	N/A	16.13%	N/A
PACS PACS Group	N/A	N/A	N/A	N/A	N/A
SEM Select Medical	$0.25	1.51%	N/A	23.58%	N/A

Latest SEM, ATAI, PACS, and CON Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/5/2026	CON Concentra Group Holdings Parent	quarterly	$0.0625	0.72%	8/20/2026	8/20/2026	8/28/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
CON Concentra Group Holdings Parent	3.22	1.38	1.38
PACS PACS Group	0.21	0.91	0.91
SEM Select Medical	0.88	1.15	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
CON Concentra Group Holdings Parent	N/A
PACS PACS Group	N/A
SEM Select Medical	89.48%

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
CON Concentra Group Holdings Parent	8.10%
PACS PACS Group	70.10%
SEM Select Medical	16.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.86 million	297.43 million	Optionable
CON Concentra Group Holdings Parent	13,133	127.52 million	117.19 million	N/A
PACS PACS Group	47,455	158.27 million	47.32 million	Optionable
SEM Select Medical	45,300	123.94 million	104.06 million	Optionable

SEM, ATAI, PACS, and CON Headlines

Recent News About These Companies

Select Medical stock faces appraisal battle over $3.9 billion take-private price

August 31, 2026 | ad-hoc-news.deA

Select Medical Holdings Corporation

July 12, 2026 | edition.cnn.com

Select Medical Holdings Corporation Acquired by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS

June 30, 2026 | finance.yahoo.com

Select Medical Holdings Corporation Acquired by Consortium Led by Robert A. Ortenzio, Martin F.

June 30, 2026 | prnewswire.com

Select Medical Holdings Corporation Announces Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS

June 26, 2026 | finance.yahoo.com

Select Medical Holdings Corporation Announces Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F.

June 26, 2026 | prnewswire.com

$SEM Investigation Notice: BFA Law is Investigating the Select Medical Board for Breaching its Duties to Shareholders after $16.50 Acquisition Announced

June 17, 2026 | globenewswire.com

SEM Shareholder News: Select Medical Investors may have Rights in Investigation over $16.50 per share Acquisition – Current Shareholders Urged to Contact BFA Law

June 15, 2026 | globenewswire.com

$SEM Stock Drop Reminder: Select Medical Announces $16.50 per share Acquisition – BFA Law's Investigation into the Board is Ongoing

June 12, 2026 | globenewswire.com

Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private Transaction

June 10, 2026 | globenewswire.com

Select Medical Investigation: Select Medical (SEM) Board Investigated after Announcing $16.50 per share Acquisition – Contact BFA Law if You Hold Shares

June 10, 2026 | globenewswire.com

Attention Select Medical Investors: Kaskela Law LLC is Investigating the Proposed $16.50 Per Share Shareholder Buyout and Encourages Investors to Contact the Firm to Protect Their Investment

June 9, 2026 | globenewswire.com

$SEM Securities Notice: BFA Law Notifies Select Medical Shareholders the Pending Investigation into the $16.50 per share Acquisition

June 8, 2026 | globenewswire.com

$SEM Stock Notification: Current Shareholder of Select Medical? Contact BFA Law about its Ongoing Investigation into the Board Over $16.50 per share Acquisition

June 5, 2026 | globenewswire.com

Kaskela Law LLC Announces Investigation into Fairness of $16.50 Per Share Select Medical Holdings (SEM) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

June 4, 2026 | businesswire.com

SEM Alert: BFA Law Reminds Select Medical Shareholders of its Pending Investigation into the Board after $16.50 per share Acquisition is Announced

June 4, 2026 | businesswire.com

SEM Legal Claims: The Select Medical Board may have Breached its Fiduciary Duties to Investors – Contact BFA Law about its Pending Investigation into the Merger

June 3, 2026 | globenewswire.com

SEM Stock Notification: Select Medical Board Investigated for Breaching its Duties to Investors Over $16.50 Acquisition Price

June 2, 2026 | prnewswire.com

Are SEM, AFBI, BLD, QXO Obtaining Fair Deals for their Shareholders?

June 2, 2026 | prnewswire.com

Select Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Select Medical Holdings Corporation - SEM

June 1, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SEM, ATAI, PACS, and CON Company Descriptions

Atai Beckley NASDAQ:ATAI

$7.39 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Concentra Group Holdings Parent NYSE:CON

$34.44 -0.03 (-0.09%)

As of 09/4/2026 03:58 PM Eastern

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers' compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.

PACS Group NYSE:PACS

$42.54 +0.04 (+0.09%)

As of 09/4/2026 03:58 PM Eastern

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

Select Medical NYSE:SEM

Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. It operates in four segments: Critical Illness Recovery Hospital, Rehabilitation Hospital, Outpatient Rehabilitation, and Concentra. The Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. The Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. The Concentra segment operates and provides occupational health centers, telemedicine platforms, onsite clinics, and contract services at employer worksites that deliver occupational health services, consumer health, physical therapy, and preventive care. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEM, ATAI, PACS, and CON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEM, ATAI, PACS, and CON Earnings

Compare Dividends

Latest SEM, ATAI, PACS, and CON Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEM, ATAI, PACS, and CON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SEM, ATAI, PACS, and CON Company Descriptions

Atai Beckley NASDAQ:ATAI

Concentra Group Holdings Parent NYSE:CON

PACS Group NYSE:PACS

Select Medical NYSE:SEM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools